• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

粪便钙卫蛋白用于预测克罗恩病患者的复发和活动:一项荟萃分析

Fecal Calprotectin for predicting Relapse and Activity in Patients with Crohn's Disease: A Meta-analysis.

作者信息

Zhuge Ying, Huang Qiu-Ping, Li Qing, Wang Jun-Shan

机构信息

Department of Cardiology, Affiliated Shanghai First People's Hospital, Shanghai Jiao Tong University, Shanghai, China.

Department of Internal Medicine, Affiliated Shanghai First People's Hospital, Shanghai Jiao Tong University, Shanghai, China.

出版信息

Euroasian J Hepatogastroenterol. 2016 Jul-Dec;6(2):116-124. doi: 10.5005/jp-journals-10018-1182. Epub 2016 Dec 1.

DOI:10.5005/jp-journals-10018-1182
PMID:29201742
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5578578/
Abstract

AIMS

We aimed to perform a meta-analysis of the predictive capacity of fecal calprotectin (FC) in activity and relapse of Crohn's disease (CD).

MATERIALS AND METHODS

MEDLINE, EMBASE, and the Cochrane Library databases were searched systematically. Pooled sensitivity, specificity, and other diagnostic indices were evaluated.

RESULTS

A total of 1,252 CD patients from 18 different studies were analyzed. The pooled sensitivity and specificity of FC at a cutoff value of 50 μg/g to predict activity of CD were 0.91 [95% confidence interval (CI): 0.87-0.95] and 0.47 (95% CI: 0.35-0.59) respectively. The pooled sensitivity and specificity of FC at a cutoff value of larger than 150 μg/g to monitor relapse of CD was 0.75 (95% CI: 0.67-0.82) and 0.71 (95% CI: 0.66-0.76) respectively. The area under the summary receiver operating characteristic (SROC) curve of FC for detecting CD activity was 0.78 (50 μg/g), 0.88 (100 μg/g), 0.85 (>150 μg/g), and the diagnostic odds ratio (DOR) was 10.21 (50 μg/g), 10.20 (100 μg/g), 11.68 (>150 μg/g) respectively.

CONCLUSION

As a simple and noninvasive marker, FC is useful to predict the activity and relapse in CD patients, and the capacity of FC to predict CD activity was superior to its application in monitoring relapse of CD.

HOW TO CITE THIS ARTICLE

Zhuge Y, Huang Q-P, Li Q, Wang J-S. Fecal Calprotectin for predicting Relapse and Activity in Patients with Crohn's Disease: A Meta-analysis. Euroasian J Hepato-Gastroenterol 2016;6(2):116-124.

摘要

目的

我们旨在对粪便钙卫蛋白(FC)在克罗恩病(CD)活动期和复发方面的预测能力进行荟萃分析。

材料与方法

系统检索MEDLINE、EMBASE和Cochrane图书馆数据库。评估合并敏感度、特异度及其他诊断指标。

结果

共分析了来自18项不同研究的1252例CD患者。FC以50μg/g为临界值预测CD活动期的合并敏感度和特异度分别为0.91[95%置信区间(CI):0.87 - 0.95]和0.47(95%CI:0.35 - 0.59)。FC以大于150μg/g为临界值监测CD复发的合并敏感度和特异度分别为0.75(95%CI:0.67 - 0.82)和0.71(95%CI:0.66 - 0.76)。FC检测CD活动期的汇总受试者工作特征(SROC)曲线下面积分别为0.78(50μg/g)、0.88(100μg/g)、0.85(>150μg/g),诊断比值比(DOR)分别为10.21(50μg/g)、10.20(100μg/g)、11.68(>150μg/g)。

结论

作为一种简单且无创的标志物,FC对预测CD患者的活动期和复发有用,且FC预测CD活动期的能力优于其在监测CD复发方面的应用。

如何引用本文

Zhuge Y, Huang Q-P, Li Q, Wang J-S. Fecal Calprotectin for predicting Relapse and Activity in Patients with Crohn's Disease: A Meta-analysis. Euroasian J Hepato-Gastroenterol 2016;6(2):116 - 124.

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23fd/5578578/37d8205e246c/ejohg-06-116-i006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23fd/5578578/e73eee78cb18/ejohg-06-116-i001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23fd/5578578/6c6674a74f1c/ejohg-06-116-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23fd/5578578/a8e537b016f8/ejohg-06-116-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23fd/5578578/d8b33ea59e82/ejohg-06-116-i002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23fd/5578578/d451000b5c32/ejohg-06-116-i003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23fd/5578578/f45785184136/ejohg-06-116-i004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23fd/5578578/8276dc742d85/ejohg-06-116-i005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23fd/5578578/37d8205e246c/ejohg-06-116-i006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23fd/5578578/e73eee78cb18/ejohg-06-116-i001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23fd/5578578/6c6674a74f1c/ejohg-06-116-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23fd/5578578/a8e537b016f8/ejohg-06-116-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23fd/5578578/d8b33ea59e82/ejohg-06-116-i002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23fd/5578578/d451000b5c32/ejohg-06-116-i003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23fd/5578578/f45785184136/ejohg-06-116-i004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23fd/5578578/8276dc742d85/ejohg-06-116-i005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23fd/5578578/37d8205e246c/ejohg-06-116-i006.jpg

相似文献

1
Fecal Calprotectin for predicting Relapse and Activity in Patients with Crohn's Disease: A Meta-analysis.粪便钙卫蛋白用于预测克罗恩病患者的复发和活动:一项荟萃分析
Euroasian J Hepatogastroenterol. 2016 Jul-Dec;6(2):116-124. doi: 10.5005/jp-journals-10018-1182. Epub 2016 Dec 1.
2
Fecal calprotectin in predicting relapse of inflammatory bowel diseases: a meta-analysis of prospective studies.粪便钙卫蛋白预测炎症性肠病复发:前瞻性研究的荟萃分析。
Inflamm Bowel Dis. 2012 Oct;18(10):1894-9. doi: 10.1002/ibd.22861. Epub 2012 Jan 11.
3
Fecal calprotectin for the prediction of small-bowel Crohn's disease by capsule endoscopy: a systematic review and meta-analysis.通过胶囊内镜检查,粪便钙卫蛋白对小肠克罗恩病的预测作用:一项系统评价和荟萃分析
Eur J Gastroenterol Hepatol. 2016 Oct;28(10):1137-44. doi: 10.1097/MEG.0000000000000692.
4
Optimal Range of Fecal Calprotectin for Predicting Mucosal Healing in Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.粪便钙卫蛋白预测炎症性肠病患者黏膜愈合的最佳范围:一项系统评价和荟萃分析
Visc Med. 2021 Oct;37(5):338-348. doi: 10.1159/000514196. Epub 2021 Jan 21.
5
Low fecal calprotectin predicts clinical remission in Crohn's disease patients: the simple answer to a challenging question.低粪便钙卫蛋白可预测克罗恩病患者的临床缓解:对一个具有挑战性问题的简单答案。
Scand J Gastroenterol. 2019 Jan;54(1):49-54. doi: 10.1080/00365521.2018.1549683. Epub 2019 Jan 20.
6
Diagnostic Accuracy of Fecal Calprotectin for Predicting Relapse in Inflammatory Bowel Disease: A Meta-Analysis.粪便钙卫蛋白预测炎症性肠病复发的诊断准确性:一项荟萃分析。
J Clin Med. 2023 Feb 2;12(3):1206. doi: 10.3390/jcm12031206.
7
Diagnostic Accuracy of Fecal Calprotectin for the Detection of Small Bowel Crohn's Disease through Capsule Endoscopy: An Updated Meta-Analysis and Systematic Review.粪便钙卫蛋白检测胶囊内镜对小肠克罗恩病的诊断准确性:一项更新的荟萃分析和系统评价。
Gut Liver. 2021 Sep 15;15(5):732-741. doi: 10.5009/gnl20249.
8
Meta-analysis: fecal calprotectin for assessment of inflammatory bowel disease activity.荟萃分析:粪便钙卫蛋白用于评估炎症性肠病活动度
Inflamm Bowel Dis. 2014 Aug;20(8):1407-15. doi: 10.1097/MIB.0000000000000057.
9
Fecal calprotectin for detection of postoperative endoscopic recurrence in Crohn's disease: systematic review and meta-analysis.粪便钙卫蛋白用于检测克罗恩病术后内镜复发:系统评价与荟萃分析
Therap Adv Gastroenterol. 2018 Jul 8;11:1756284818785571. doi: 10.1177/1756284818785571. eCollection 2018.
10
Fecal calprotectin is a strong predictive marker of relapse in Chinese patients with Crohn's disease: a two-year prospective study.粪便钙卫蛋白是中国克罗恩病患者复发的有力预测标志物:一项为期两年的前瞻性研究。
Scand J Gastroenterol. 2017 Oct;52(10):1113-1119. doi: 10.1080/00365521.2017.1346704. Epub 2017 Jul 4.

本文引用的文献

1
Faecal calprotectin assay after induction with anti-Tumour Necrosis Factor α agents in inflammatory bowel disease: Prediction of clinical response and mucosal healing at one year.抗肿瘤坏死因子α制剂诱导治疗炎症性肠病后粪便钙卫蛋白检测:一年时临床反应和黏膜愈合的预测
Dig Liver Dis. 2014 Nov;46(11):974-9. doi: 10.1016/j.dld.2014.07.013. Epub 2014 Aug 2.
2
Meta-analysis: fecal calprotectin for assessment of inflammatory bowel disease activity.荟萃分析:粪便钙卫蛋白用于评估炎症性肠病活动度
Inflamm Bowel Dis. 2014 Aug;20(8):1407-15. doi: 10.1097/MIB.0000000000000057.
3
Faecal calprotectin and lactoferrin as markers for monitoring disease activity and predicting clinical recurrence in patients with Crohn's disease after ileocolonic resection: A prospective pilot study.
粪便钙卫蛋白和乳铁蛋白作为监测克罗恩病患者回肠结肠切除术后疾病活动度和预测临床复发的标志物:一项前瞻性试点研究。
United European Gastroenterol J. 2013 Oct;1(5):368-74. doi: 10.1177/2050640613501818.
4
Capsule endoscopic findings correlate with fecal calprotectin and C-reactive protein in patients with suspected small-bowel Crohn's disease.在疑似小肠克罗恩病患者中,胶囊内镜检查结果与粪便钙卫蛋白及C反应蛋白相关。
Scand J Gastroenterol. 2014 Sep;49(9):1084-90. doi: 10.3109/00365521.2014.920915. Epub 2014 May 22.
5
A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohn's disease.一项前瞻性队列研究,旨在确定血清英夫利昔单抗浓度与腔型克罗恩病患者疗效之间的关系。
Aliment Pharmacol Ther. 2014 May;39(10):1126-35. doi: 10.1111/apt.12733. Epub 2014 Apr 1.
6
Serum ficolin-2 correlates worse than fecal calprotectin and CRP with endoscopic Crohn's disease activity.血清纤维胶凝蛋白-2与内镜下克罗恩病活动度的相关性比粪便钙卫蛋白和CRP更差。
J Crohns Colitis. 2014 Sep;8(9):1125-32. doi: 10.1016/j.crohns.2014.02.014. Epub 2014 Mar 11.
7
A prospective evaluation of the predictive value of faecal calprotectin in quiescent Crohn's disease.粪便钙卫蛋白在静止期克罗恩病中预测价值的前瞻性评估。
J Crohns Colitis. 2014 Sep;8(9):1022-9. doi: 10.1016/j.crohns.2014.01.029. Epub 2014 Feb 22.
8
Association between disease duration and usefulness of fecal calprotectin measurement in patients with Crohn's disease.克罗恩病患者的病程与粪便钙卫蛋白检测的效用之间的关联。
Pol Arch Med Wewn. 2014;124(1-2):51-7. Epub 2013 Dec 4.
9
Fecal calprotectin one year after ileocaecal resection for Crohn's disease--a comparison with findings at ileocolonoscopy.克罗恩病回盲部切除术后一年的粪便钙卫蛋白——与回结肠镜检查结果的比较
J Crohns Colitis. 2014 Aug;8(8):789-95. doi: 10.1016/j.crohns.2013.12.015. Epub 2014 Jan 11.
10
Tumor necrosis factor-α antibodies (infliximab, adalimumab and certolizumab) in Crohn's disease: systematic review and meta-analysis.肿瘤坏死因子-α 抗体(英夫利昔单抗、阿达木单抗和培塞利珠单抗)在克罗恩病中的应用:系统评价和荟萃分析。
Arch Med Sci. 2013 Oct 31;9(5):765-79. doi: 10.5114/aoms.2013.38670. Epub 2013 Nov 5.